Chevy Chase Trust Holdings LLC Buys 16,678 Shares of Natera, Inc. (NASDAQ:NTRA)

Chevy Chase Trust Holdings LLC increased its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 3.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 566,549 shares of the medical research company's stock after buying an additional 16,678 shares during the quarter. Chevy Chase Trust Holdings LLC owned 0.42% of Natera worth $80,116,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. LRI Investments LLC acquired a new position in Natera in the fourth quarter valued at about $29,000. Rakuten Securities Inc. boosted its holdings in shares of Natera by 117.8% in the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after acquiring an additional 119 shares in the last quarter. ORG Partners LLC bought a new stake in Natera during the 1st quarter worth approximately $32,000. Blue Trust Inc. increased its holdings in Natera by 223.7% during the 4th quarter. Blue Trust Inc. now owns 301 shares of the medical research company's stock valued at $48,000 after purchasing an additional 208 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in Natera by 372.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after purchasing an additional 261 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Piper Sandler upped their price target on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Thursday, May 15th. Robert W. Baird upped their target price on shares of Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. BTIG Research reaffirmed a "buy" rating on shares of Natera in a report on Friday, February 28th. Finally, UBS Group increased their price objective on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $184.63.

Natera Stock Performance

NASDAQ:NTRA traded up $1.50 on Tuesday, reaching $171.87. The company's stock had a trading volume of 935,374 shares, compared to its average volume of 1,408,278. The firm has a market cap of $23.47 billion, a PE ratio of -116.92 and a beta of 1.74. The business's 50-day moving average price is $157.44 and its two-hundred day moving average price is $158.45. Natera, Inc. has a 1-year low of $92.14 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. Natera's quarterly revenue was up 36.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.56) EPS. As a group, sell-side analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Insider Activity at Natera

In other news, CEO Steven Leonard Chapman sold 9,563 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $138.41, for a total transaction of $1,323,614.83. Following the completion of the transaction, the chief executive officer now directly owns 212,541 shares of the company's stock, valued at $29,417,799.81. This trade represents a 4.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Burkes Brophy sold 2,562 shares of the business's stock in a transaction on Monday, March 31st. The stock was sold at an average price of $138.41, for a total transaction of $354,606.42. Following the completion of the sale, the chief financial officer now directly owns 75,557 shares in the company, valued at approximately $10,457,844.37. This represents a 3.28% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 59,755 shares of company stock valued at $8,898,589. 7.60% of the stock is owned by corporate insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.